Prescott R W, Johnston D G, Taylor P K, Haigh J, Weightman D R, Hall K, Cook D B
J Endocrinol Invest. 1985 Feb;8(1):49-54. doi: 10.1007/BF03350639.
Certain hyperprolactinemic patients have an obvious pituitary tumor while others with normal pituitary radiology may or may not harbor a pituitary microadenoma. A variety of biochemical tests have been proposed to distinguish between those with and those without pituitary tumors. The aims of this study were: firstly to examine these tests to assess their efficacy in differentiating between patients with radiologically-demonstrated pituitary tumors and normal controls; and secondly to establish if those hyperprolactinemic patients with normal radiology formed two distinct groups biochemically as might be expected if some did and some did not have tumors. The prolactin (PRL) and thyroid stimulating hormone (TSH) response to domperidone and the PRL response to TRH and insulin-induced hypoglycemia have thus been examined in hyperprolactinemic subjects with and without radiological evidence of an adenoma and in normal controls. The basal serum PRL was similar in patients with and without radiological evidence of a pituitary adenoma. The serum PRL response to all stimuli studied, expressed as a percentage of initial values, was blunted in patients with known pituitary tumors with total separation from values in control subjects. Results for patients with normal pituitary radiology were similar to those for patients with tumors with minimal overlap with controls. The peak TSH increment after domperidone was exaggerated in patients with known tumors, but overlap with control values was observed in 25%. In patients with normal radiology the peak TSH increment after domperidone was similarly increased but again overlap with control values occurred in 28%. Cluster analysis showed no evidence of two subgroups of response with in the hyperprolactinemic patients.(ABSTRACT TRUNCATED AT 250 WORDS)
某些高催乳素血症患者有明显的垂体肿瘤,而其他垂体放射学检查正常的患者可能有也可能没有垂体微腺瘤。已经提出了多种生化检测方法来区分有垂体肿瘤和无垂体肿瘤的患者。本研究的目的是:首先,检验这些检测方法,评估其在区分有放射学证据的垂体肿瘤患者和正常对照者方面的有效性;其次,确定那些放射学检查正常的高催乳素血症患者在生化方面是否形成两个不同的组,就像预期的那样,一些患者有肿瘤而一些患者没有。因此,对有和没有腺瘤放射学证据的高催乳素血症患者以及正常对照者,检测了催乳素(PRL)和促甲状腺激素(TSH)对多潘立酮的反应以及PRL对促甲状腺激素释放激素(TRH)和胰岛素诱导的低血糖的反应。有和没有垂体腺瘤放射学证据的患者基础血清PRL相似。所有研究刺激下血清PRL的反应,以初始值的百分比表示,在已知有垂体肿瘤的患者中减弱,与对照者的值完全分开。垂体放射学检查正常的患者结果与有肿瘤的患者相似,与对照者有最小程度的重叠。已知有肿瘤的患者多潘立酮后TSH峰值增量夸大,但25%的患者与对照值有重叠。放射学检查正常的患者多潘立酮后TSH峰值增量同样增加,但28%的患者再次与对照值有重叠。聚类分析显示高催乳素血症患者中没有反应的两个亚组的证据。(摘要截短于250字)